Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Xeltis

Xeltis
2006 FOUNDED
PRIVATE STATUS
31-40 EMPLOYEES
Series D LATEST DEAL TYPE
$12.2M LATEST DEAL AMOUNT
6 INVESTORS
Description

Developer of medical devices designed for Endogenous Tissue Restoration (ETR). The company's medical device platform comprises bioabsorbable cardiovascular valves and vessels that use endogenous tissue restoration technology, enabling the patient's own body to naturally form a new heart valve through a therapeutic approach.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Primary Office
  • Seefeldstrasse 35
  • 8008 Zurich
  • Switzerland

+41 044 000 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Xeltis’s full profile, request a free trial.

Xeltis Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series D) 05-Sep-2019 $12.2M 000.00 Completed Clinical Trials - General
3. Later Stage VC (Series C) 15-Nov-2017 000.00 000.00 Completed Clinical Trials - General
2. Later Stage VC (Series B) 24-Sep-2015 $33.7M $33.7M Completed Clinical Trials - General
1. Early Stage VC Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Xeltis Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
QT Vascular Corporation Singapore, Singapore 0000 000000000 0000
000000000 Corporate Backed or Acquired Framingham, MA 000 00000 000000&0 00000
0000000 0000000000 Venture Capital-Backed Kirkland, WA 00 00000 00000000000 00000
000 Formerly PE-Backed Leesburg, VA 000 00000 000000&0 00000
000000 0000000000 Failed Transaction (M&A) Marlborough, MA 00000 000000&0
To view this company’s complete list of competitors, request access »

Xeltis Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Ysios Capital Venture Capital Minority 000 0000 000000 0
Kurma Partners Venture Capital Minority 000 0000 000000 0
Life Sciences Partners Venture Capital Minority 000 0000 000000 0
StartAngels Network Angel Group Minority 000 0000 000000 0
VI Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Xeltis Executive Team (30)

Name Title Board
Seat
Contact
Info
Eliane Schutte Chief Executive Officer & Chief Development Officer
Martin De Groot Chief Financial Officer & Board Member
Martijn Cox Ph.D Chief Technology Officer & Co-Founder
Hugo Ploegmakers Manager Production and Supplier Quality
Mark La Meir Ph.D Independent Clinal Advisor

7 Former Executives

You’re viewing 5 of 30 executives. Get the full list »

Xeltis Board Members (10)

Name Representing Role Since Contact
Info
Christian Wenger Ph.D Self Board Member 000 0000
Clemens Van Blitterswijk Ph.D Life Sciences Partners Board Member 000 0000
Karen Wagner Ysios Capital Board Member 000 0000
Martin De Groot Xeltis Chief Financial Officer & Board Member 000 0000
Michael Colson Self Chairman of the Scientific Advisory Board 000 0000

4 Former Board Members

You’re viewing 5 of 10 board members. Get the full list »